Thalidomide - Shanghai Pharmaceuticals Holding

Drug Profile

Thalidomide - Shanghai Pharmaceuticals Holding

Latest Information Update: 01 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Pharmaceutical
  • Developer Shanghai Pharmaceuticals Holding
  • Class Antileprotics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Ankylosing spondylitis

Most Recent Events

  • 31 Mar 2017 No recent reports of development identified - Phase-II for Ankylosing spondylitis in China (PO)
  • 29 Apr 2016 Biomarkers information updated
  • 01 Feb 2013 Phase-II clinical trials in Ankylosing spondylitis in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top